Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective increased by research analysts at B. Riley from $27.00 to $40.00 in a report released on Thursday, Stock Target Advisor reports. The firm presently has a “buy” rating on the stock. B. Riley’s target price would indicate a potential upside of 112.65% from the company’s current price.
A number of other brokerages have also weighed in on APLS. Cantor Fitzgerald reiterated a “buy” rating and set a $52.00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday, June 27th. Zacks Investment Research lowered shares of Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, June 18th. Finally, Cowen assumed coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, July 10th. They set an “outperform” rating and a $40.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $36.00.
APLS opened at $18.81 on Thursday. The stock has a market cap of $1.05 billion and a P/E ratio of -5.13. The company has a debt-to-equity ratio of 0.12, a current ratio of 26.02 and a quick ratio of 26.02. Apellis Pharmaceuticals has a fifty-two week low of $12.45 and a fifty-two week high of $32.00.
Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, July 31st. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.14). analysts predict that Apellis Pharmaceuticals will post -2.2 earnings per share for the current year.
Large investors have recently modified their holdings of the business. Hillhouse Capital Management Ltd. raised its stake in Apellis Pharmaceuticals by 203.0% in the second quarter. Hillhouse Capital Management Ltd. now owns 4,328,289 shares of the company’s stock valued at $95,222,000 after purchasing an additional 2,899,718 shares in the last quarter. venBio Partners L.P. acquired a new stake in shares of Apellis Pharmaceuticals in the second quarter worth approximately $72,482,000. BlackRock Inc. boosted its stake in shares of Apellis Pharmaceuticals by 152.9% in the second quarter. BlackRock Inc. now owns 2,798,968 shares of the company’s stock worth $61,578,000 after acquiring an additional 1,692,121 shares during the last quarter. FMR LLC boosted its stake in shares of Apellis Pharmaceuticals by 34.6% in the second quarter. FMR LLC now owns 1,343,140 shares of the company’s stock worth $29,549,000 after acquiring an additional 345,376 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Apellis Pharmaceuticals by 150.2% in the second quarter. Victory Capital Management Inc. now owns 932,753 shares of the company’s stock worth $20,520,000 after acquiring an additional 559,913 shares during the last quarter. Hedge funds and other institutional investors own 57.54% of the company’s stock.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Further Reading: Do Tariffs Work?
Receive News & Ratings for Apellis Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.